Efficacy of IV RO7283420 among group I patients as defined by the ELN 2017 recommendations
| Best overall response, n (%) . | Efficacy-evaluable patients (n = 42) . |
|---|---|
| Objective response (CRMRD, CR, CRi, PR) | 3 (7.1) |
| CRMRD− | 0 |
| CR | 2 (4.8) |
| CRi | 1 (2.4) |
| PR | 0 |
| SD | 20 (47.6) |
| PD | 16 (38.1) |
| Missing/not evaluable | 3 (7.1) |
| Best overall response, n (%) . | Efficacy-evaluable patients (n = 42) . |
|---|---|
| Objective response (CRMRD, CR, CRi, PR) | 3 (7.1) |
| CRMRD− | 0 |
| CR | 2 (4.8) |
| CRi | 1 (2.4) |
| PR | 0 |
| SD | 20 (47.6) |
| PD | 16 (38.1) |
| Missing/not evaluable | 3 (7.1) |
CR, complete remission; CRi, complete remission with incomplete hematologic recovery; CRMRD-, complete remission with absence of measurable residual disease; ELN, European LeukemiaNet; IV, intravenous; PD, progressive disease; PR, partial remission; SD, stable disease.